Oligodendroglioma – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Oligodendroglioma – Drugs In Development, 2024 report and make more profitable business decisions.
Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.
The Oligodendroglioma drugs in development market research report provide comprehensive information on the therapeutics under development for Oligodendroglioma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Oligodendroglioma | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 28 molecules, with 21 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Oligodendroglioma therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Oligodendroglioma pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Oligodendroglioma treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
AbbVie IncAngioChem Inc
Aveta Biomics Inc
Bayer AG
BioMed Valley Discoveries Inc
Boehringer Ingelheim International GmbH
Capital Medical University
Chimerix Inc
Eli Lilly and Co
Fore Biotherapeutics Inc
German Cancer Research Center
GSK plc
Immatics NV
Ipsen SA
Istari Oncology Inc
Les Laboratoires Servier SAS
Mayo Clinic
MimiVax LLC
Nascent Biotech Inc
Nationwide Children's Hospital
Nerviano Medical Sciences SRL
Novartis AG
Oblato Inc
Royan Institute
TheraBiologics Inc
UCLAs Jonsson Comprehensive Cancer Center
Wurzburg University Hospital
Xynomic Pharmaceuticals Holdings Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Oligodendroglioma reports